Singh Desh Deepak, Haque Shafiul, Singh Abhishek Kumar, Yadav Dharmendra Kumar
Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India.
Department of Nursing, College of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia and School of Medicine, Universidad Espiritu Santo, Samborondon, Ecuador.
Neurooncol Adv. 2025 Jun 24;7(1):vdaf135. doi: 10.1093/noajnl/vdaf135. eCollection 2025 Jan-Dec.
Glioblastomas (GBMs) originate from glial cells and are characterized by aggressive growth and poor prognosis. Despite advances in surgical resection, complete elimination remains challenging, often leading to recurrence that is resistant to standard therapies. Immunotherapy and conventional treatments show promise in enhancing therapeutic outcomes across various cancers. Researchers continue to explore new treatments, particularly radiation, chemotherapy, and surgery; however, glioblastoma remains highly challenging, with only modest improvements in survival. Recent progress in immunotherapy, especially with tumor vaccines such as peptide-based and cell-based options (eg, dendritic cell vaccines), represents significant advancements despite the limitations observed in current clinical trials. This article reviews recent developments in vaccine-based immunotherapy for glioblastoma treatment.
胶质母细胞瘤（GBM）起源于神经胶质细胞，具有生长侵袭性和预后不良的特点。尽管手术切除取得了进展，但完全切除仍具有挑战性，常常导致复发，且复发对标准治疗具有抗性。免疫疗法和传统治疗方法在提高各种癌症的治疗效果方面显示出前景。研究人员继续探索新的治疗方法，特别是放疗、化疗和手术；然而，胶质母细胞瘤仍然极具挑战性，生存率仅有适度提高。免疫疗法的最新进展，尤其是基于肽和基于细胞的肿瘤疫苗（如树突状细胞疫苗）等肿瘤疫苗，尽管在当前临床试验中观察到存在局限性，但仍代表了重大进展。本文综述了基于疫苗的免疫疗法在胶质母细胞瘤治疗中的最新进展。
